Substituted Lactams for Glaucoma Treatment
Solution Overview
Problem
Current treatments for glaucoma lack effective compounds that can reliably reduce intraocular pressure, which is crucial for delaying or preventing the onset and progression of primary open angle glaucoma and associated vision loss.
Innovation Solution
Development of specific compounds with formulas that include organic acid functional groups, amides, esters, hydroxymethyl, ethers, or tetrazolyl functional groups, which can be administered topically to reduce intraocular pressure and treat glaucoma, with stability ensuring they remain effective for storage and use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional glaucoma treatments are used, then intraocular pressure reduction is achieved, but the compounds lack stability for storage and long-term use
Solution Approach 1:
The patent modifies the chemical structure of lactam compounds by changing parameters such as substituting carbon atoms with heteroatoms (S or O) in the chain A, and introducing specific functional groups (Y) at the 5-position of the pyrrolidin-2-one core. These parameter changes result in compounds that maintain therapeutic efficacy while improving storage stability for at least 12 hours under normal conditions.
2Stability of the object's composition
If new compound structures are developed to improve stability, then storage reliability is enhanced, but the complexity of synthesis and formulation increases
Solution Approach 1:
The patent creates a universal class of lactam compounds with a core pyrrolidin-2-one structure that can be adapted for multiple therapeutic applications. The general formula allows for systematic variation of chains (A), substituents (G, G'), and functional groups (Y), enabling a single structural framework to address both stability requirements and therapeutic efficacy without requiring entirely new formulation approaches for each variant.
3Ease of operation
If topical administration is used to treat glaucoma, then direct eye delivery is achieved, but the compounds must maintain stability in aqueous solutions
Solution Approach 1:
The patent introduces hydrolyzable functional groups (Y) such as carboxylic acid, ester, or amide at the 5-position of the pyrrolidin-2-one core, which can be modified to improve aqueous stability. The general formula allows selection of Y groups that balance aqueous solution stability with the ability to form stable emulsions for topical administration, ensuring compounds remain effective in ocular formulations.
Data Source
AI summary
Disclosed herein are compounds having a formula: (I) Compositions, methods, and medicaments related thereto are also disclosed.



